TNXP
TNXP
NASDAQ · Biotechnology

Tonix Pharmaceuticals Holdin

$14.44
+0.35 (+2.48%)
As of May 16, 2:05 AM ET ·
Financial Highlights (FY 2026)
Revenue
23.95M
Net Income
-226,648,175
Gross Margin
49.3%
Profit Margin
-946.2%
Rev Growth
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 49.3% 59.2% 59.2% 59.2%
Operating Margin -975.0% -23.9% -24.9% -24.3%
Profit Margin -946.2% -24.5% -29.4% -31.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 23.95M 84.57M 86.26M 76.53M
Gross Profit 11.82M 50.02M 51.02M 45.27M
Operating Income -233,536,900 -20,221,333 -21,451,311 -18,634,068
Net Income -226,648,175 -20,699,385 -25,319,011 -23,908,785
Gross Margin 49.3% 59.2% 59.2% 59.2%
Operating Margin -975.0% -23.9% -24.9% -24.3%
Profit Margin -946.2% -24.5% -29.4% -31.2%
Rev Growth +3.2% +20.0% +0.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 97.43M 108.81M 97.98M
Total Equity 167.70M 160.32M 155.36M
D/E Ratio 0.58 0.68 0.63
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -230,544,559 -24,990,141 -25,196,528 -24,930,968
Free Cash Flow -20,292,095 -20,848,476 -17,728,438